J&J’s new partnership with Elektrofi; Enyo raises €39M; Arrowhead's $450M offering
Plus, news about TC BioPharm, BioCentriq, 4D Molecular and Arbor Biotechnologies, and Longboard Pharmaceuticals:
Johnson & Johnson teams up with Elektrofi: The Boston biotech will work with J&J’s Janssen Biotech to create an at-home self-administered under-the-skin version of a “lead oncology asset.” Elektrofi snagged an upfront payment of $18 million and could receive $155 million or more in milestones per target in the multi-target pact. — Kyle LaHucik
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.